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Background: In 20e25% of patients with biopsy-proven DCIS underestimation occurs. Sentinel lymph
node biopsy (SLNB) is offered to patients with biopsy-proven ductal carcinoma in situ (DCIS) and a high
risk of occult invasive cancer. However, assessment of high risk is controversial. We aimed to improve
selection of patients for SLNB with preoperative breast magnetic resonance imaging (MRI).
Methods: In this prospective observational study, MRI was offered to all subsequent patients with a
biopsy-proven DCIS admitted to a large Dutch teaching hospital between April 2012 and March 2017. MRI
images were analysed for signs of invasive cancer and the results were compared with the pathologic
results after surgical treatment. The diagnostic accuracy of additional MRI in detecting occult invasive
cancer was determined.
Results: Of 211 patients eligible for additional MRI analysis, 149 underwent breast MRI. The majority
(67%) received breast-conserving therapy, and the underestimation rate was 20%. Subsequent to MRI
analysis, 20 additional invasive diagnostic procedures were performed. Occult invasive cancer was
suspected on MRI in 46 patients (31%) and was confirmed in 18 (12%). In this study, breast MRI had a
sensitivity of 67%, a specificity of 77%, and a true negative rate of 91%.
Conclusion: Preoperative breast MRI cannot reliably predict the presence of invasive cancer in patients
with biopsy proven DCIS. Therefore, it cannot be used to in the selection of patients for a SLNB.
© 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical
Oncology. All rights reserved.Introduction
Ductal carcinoma in situ (DCIS) diagnosed at core needle biopsy
may represent occult invasive breast cancer. In 20e25% of patients
with biopsy-proven DCIS, underestimation occurs, and invasive
breast cancer is detected in the surgical specimen [1,2]. In the
management of invasive breast cancer, nodal staging is standard of
care, therefore several guidelines recommend the use of a sentinel
lymph node biopsy (SLNB) in selected patients with a high risk of
underestimation [3,4].3318, AL Dordrecht, the
Westenend).
on for Cancer Surgery, and the EuUnderestimation has been associated with a range of factors:
biopsy device and guidance method, tumor size, palpability, grade
and mammographic features [1]. According to Dutch national
guidelines, patients with a high risk of underestimation are defined
by a high-grade DCIS on core-needle biopsy (CNB), large area
(>2.5 cm) of calcifications on mammography, and age under 55
years [5]. Another reason for SLNB is a planned mastectomy (for
oncologic reasons, or at patient’s request) since SLNB is not feasible
afterwards. After breast conserving surgery (BCS) for DCIS, a SLNB
can be performed in a second procedure if pathology showed
invasive cancer. Preferably, this should be anticipated on forehand.
Guidelines on the use of SLNB are conflicting and sometimes vague
on how to apply these risk factors to estimate high-risk DCIS. This
results in a wide and undesirable hospital variation in the use of
SLNB [3,4].ropean Society of Surgical Oncology. All rights reserved.
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as screening tool and as problem solving tool in the diagnostic
work-up of invasive cancer. However, the possible role of MRI as
problem solving tool in detecting occult invasive cancer in patients
with biopsy-proven DCIS has not yet been clearly established.
Limited data suggest that MRI may be a helpful addition for
determining appropriate treatment [6,7].
Therefore, this study evaluated the possible role of preoperative
breast MRI to detect occult invasive cancer in these patients and
thereby improve the selection for a SLNB.Methods
Study design
The study was a prospective observational study performed at a
large teaching hospital (up to four hundred treated new cases of
breast cancer per year) in the Netherlands. MRI was offered in
addition to the standard treatment to all subsequent patients who
received a biopsy diagnosis DCIS between April 2012 and March
2017. The Medical Ethical Board of the Maasstad hospital, Rotter-
dam, approved the study (protocol 2011/35).
Patients were referred via the national screening program or by
their general practitioner. Each patient received the standard
diagnostic work-up for suspect breast lesions. This work-up con-
sisted of physical breast examination, digital mammography, ul-
trasound examination of the breast and, if necessary, also axilla.
Image-guided (Affirm® Prone Breast Biopsy System Hologic) core
needle biopsies were obtained with a 9G needle (Suros®) from the
suspect lesions. An ultrasound-guided fine needle aspiration of the
axilla was performed from those axillary lymph nodes that
demonstrated focal or global cortical thickening or lacked a normal
architecture.
SLNB was offered to selected patients according to Dutch
guidelines, i.e. to patients with proven high-grade DCIS, an area
>2.5 cm of calcifications, age <55 years, and those who were
scheduled to undergo a mastectomy.
DCIS size was the size mentioned in the final pathology record.
In case of multiple operations, the maximum size was calculated as
the sum of the size of the primary operation and of all re-excisions.Patient selection
Women were included in case of a biopsy diagnosis DCIS and
age >25 years. A pre-operative MRI was offered to all patients.
Based on the patients’ decisions, two groups were formed: 1) a
non-MRI group, which included all the patients who chose not to
undergo an MRI, and 2) an MRI group, including all the patients
who chose to undergo an MRI.
Patients were excluded from the study in case of biopsy-proven
invasive carcinoma in the same breast, or if no operative treatment
was performed. In case of surgical treatment elsewhere, patients
were included and the pathology results of the operation specimen
were checked in the national registry of histopathology and
cytopathology.
Patients were also excluded from MRI in case of claustrophobia,
obesity (too large to fit into the gantry), large cup size (too large to
fit into the coil), pacemaker, known inflammatory disease (such as
rheumatoid arthritis, SLE, sarcoidosis or psoriasis), pregnancy, or
renal failure.
Patient-related variables were gathered from the electronical
medical records of our institutional database, including age,
referrer, imaging, biopsy, MRI and operation details.Magnetic resonance imaging
MRI imaging was performed after obtaining a patient’s written
informed consent to participate in the study. Patients were placed
in prone position in a dedicated phased-array breast coil. The MR
examination protocol included 1.5-T magnet strength (Philips, Best,
The Netherlands) in the following sequences: Transversal T1-
weighted TSE (repetition time msec/echo time msec shortest/ 8;
matrix, 512 x 512), transversal sT2W SPAIR (repetition time msec/
echo time msec, 3000e5000/ 80; matrix, 512 x 512), dynamic post-
contrast transversal THRIVERHR (repetition time msec/echo time
msec, shortest/shortest; flip angle 10, matrix, 256 x 256), static
post-contrast transversal THRIVEHR (repetition time msec/echo
time msec, shortes/shortest; flip angle 10, matrix, 480 x 480) Field
of view was restricted to 16e18 cm over the breast depending on
patient size, and sections were 3 mm thick or less. T1-weighted
images were acquired prior to and immediately following bolus
injection of contrast-enhanced material (0.1 mmol/kg gadolinium
[0.1 mmol/kg ¼ 0.2 ml/kg] gadolinium). After intravenous injection
of Gadolinium, the kinetics of the enhancement of breast tissue
were studied, including construction of time intensity curves of the
enhancement, using a software package of Terarecon®
All MRI images were analysed and interpreted by one dedicated
breast radiologist without knowledge of histopathologic results. In
case of doubt, the radiologist reviewed the case again in consensus
with a second dedicated breast radiologist (all with more than 20
years of experience in the field of breast imaging). The conclusion of
the MRI report was based on morphology, kinetic curves, and
contrast with surrounding tissue. The contralateral breast was
analysed for anomalies. If necessary, additional diagnostics were
performed based on the MRI report. These lesions prompting
additional diagnostic tests were all qualified BI-RADS 3 or higher.
Additional diagnostic tests consisted of addtitional target ultra-
sound of the additional lesions, and if it was found subsequent
ultrasound guided biopsy was performed. If an additional lesion
could not be found at ultrasound, additional MRI-guided biopsy
was performed. All additional diagnostic tests were performed
within one week after the initial MRI was performed.
Diagnostic accuracy
To assess the value of the additional MRI, results of the patho-
logical examination of the surgical specimen were regarded as the
gold standard. The pathologists were blinded for the MRI results
which were stored in a different electronic file system. Small
specimen up to 30 g were totally embedded in paraffin. For larger
specimen selection of tissue blocks for microscopic examination
was based on visual inspection and specimen radiography. Slides
were reviewed by pathologists with at least 20 years of experience.
These results were compared with the MRI results to calculate
sensitivity, specificity, true negative rate (TNR), positive predictive
value (PPV) and negative predictive value (NPV). The diagnostic
accuracy was additionally analysed by comparing non-high-grade
DCIS (DCIS grade I and II) to high-grade DCIS (DCIS grade III)
based on the pre-operative biopsy reports.
Statistical analysis
Patient demographics and biopsy characteristics were analysed
using descriptive analyses, presented as means with standard de-
viations, or numbers with percentages. Differences in patient de-
mographics and in operation variables between the non-MRI group
and the MRI group were identified with univariate analysis using a
chi-square test or an independent samples t-test.
A ROC curve was composed based on the sensitivity and the
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1) ‘no invasive cancer’, 2) ‘invasive cancer unlikely’, 3) ‘invasive
cancer likely to be present’, or 4) ‘invasive cancer present’. In cur-
rent clinical practice, MRI results 1 and 2 are classified as negative
test results, and MRI results 3 and 4 are classified as positive test
results. To assess whether an alternative cut-off might yield a better
balance of harms and benefits, sensitivity, specificity, and NPV
values were calculated with different values as cut-off for a positive
MRI result. Cut-off 1 represents MRI result 1 as negative test result
andMRI result 2, 3 and 4 as positive test results, cut-off 2 represents
the current clinical setting, and cut-off 3 represents MRI result 1, 2
and 3 as negative test results andMRI result 4 as positive test result.
For all test characteristics, binomial proportion confidence in-
tervals of the test characteristics were calculated with the Agresti-
Coull method. No imputations were made for missing data. Two-
sided p-values of p < 0.05 were considered statistically signifi-
cant. All statistical analyses were performed using the statistical
software IBM SPSS version 24.Results
Patient population
In total, 211 patients with a biopsy-proven DCIS were identified
as eligible for subsequent breast MRI analysis between April 2012
and March 2017 (Fig. 1). Of these patients, 62 (29%) chose not to
undergo an MRI. Patients in the non-MRI group had a mean age of
60.5 ± 10.9 years, and 63% of them were referred via the national
screening program. Eight patients (13%) had a history of breast
cancer, the majority of the patients had calcifications on mammo-
gram (87%), and 53% of the patients had a DCIS grade III diagnosis.
Patients in the MRI group (71%) had a mean age of 57.4 ± 9.3 years,
and 60% of themwere referred via the national screening program.
Twelve patients (8%) had a history of breast cancer, the majority of
the patients had calcifications on mammogram (95%), and 61% ofFig. 1. Patient selection for patienthe patients had a DCIS grade III diagnosis. Patients in the MRI
group were significantly younger than those in de non-MRI group.
Besides age, no statistically significant differences were found be-
tween the two groups with respect to patient demographics
(Table 1).
In the non-MRI group, the primary surgical treatment was in
most cases a BCS (63%) and SLNB was ultimately performed in 43
(69%) patients. Invasive cancer was detected in 26%, and 10% had
involved surgical margins. In the MRI group, 68% of the patients
were primary treated with a BCS, and SLNB was ultimately per-
formed in 108 (72%) patients. Invasive cancer was present in 18%,
and 5% had involved surgical margins. In both groups, one patient
had a bilateral mastectomy due to a synchronous invasive carci-
noma (contralateral to DCIS). No prophylactic contralateral mas-
tectomies were performed. The conversion rate to mastectomy was
6% in the MRI group and 11% in the non-MRI group. The size of the
lesion in the surgical specimen differed significantly between the
MRI and non-MRI group. Besides the size of the lesion, no statis-
tically significant differences were found between the two groups
with respect to operation characteristics (Table 1).
Preoperative breast MRI was completed in 150 patients. The
mean lesion size was 33.7 ± 24.9 mm. The majority of the patients
(71%) had a type 1 enhancement curve, and 31% had an invasive
component on MRI. Analysis of the MRI findings led to additional
diagnostics of 28 lesions (in 26 patients (17%)), 20 of whom un-
derwent an invasive procedure (See Table 2 for more details). Of all
cases with invasive additional diagnostics, five patients showed
extended DCIS and one patient was diagnosed with invasive car-
cinoma. In these cases, BCS was not possible anymore and planned
treatment was changed into mastectomy.Diagnostic accuracy
Of the 149 patients who received a breast MRI, 27 had an
invasive carcinoma in the surgical specimen and 122 had only DCISts with biopsy-proven DCIS.
Table 1
Patient demographics of 211 patients with biopsy-proven DCIS.
No pre-operative MRI (n ¼ 62) Pre-operative MRI (n ¼ 149) p-value
Mean age ± sd, years 60.5 ± 10.9 57.4 ± 9.3 0.036
Referrer
Screening program
General practitioner
Follow up Specialist
39 (63%)
13 (21%)
10 (16%)
90 (60%)
36 (24%)
22 (15%)
1 (1%)
0.804
History of breast pathology
No
Yes, malignant
Yes, Benign
49 (79%)
8 (13%)
5 (8%)
127 (85%)
12 (8%)
10 (7%)
0.512
Palpable lesion
No
Yes
48 (77%)
14 (23%)
121 (81%)
28 (19%)
0.530
Calcifications
Absent Present
8 (13%)
54 (87%)
8 (5%)
141 (95%)
0.084
Mass
Absent Present
43 (69%)
19 (31%)
115 (77%)
34 (23%)
0.232
Density mammogram
ACR 1
ACR 2
ACR 3
ACR 4
4 (7%)
32 (53%)
17 (28%)
7 (12%)
3 (2%)
78 (53%)
48 (32%)
19 (13%)
0.425
BI-RADS
BI-RADS 3
BI-RADS 4
BI-RADS 5
53 (85%)
9 (15%)
1 (1%)
137 (92%)
11 (7%)
0.215
DCIS
Grade I
Grade II
Grade III
13 (21%)
16 (26%)
33 (53%)
24 (16%)
34 (23%)
91 (61%)
0.545
Surgical treatment
BCS
Mastectomy
39 (63%)
23 (37%)
102 (68%)
47 (32%)
0.435
SLNB
No
Yes
20 (32%)
42 (48%)
45 (30%)
104 (70%)
0.768
Histopathologic result SLNB
Negative
Positive
39 (95%)
2 (5%)
101 (97%)
3 (3%)
0.622
Surgical margins
Extensive involvement
Focal involvement
Free
6 (10.3%)
8 (14%)
44 (76%)
8 (5%)
14 (10%)
122 (84%)
0.321
Invasive cancer
Absent Present
46 (74%)
16 (26%)
122 (82%)
27 (18%)
0.207
Size lesion, mean ± sd, mm 34.7 ± 32.3 26.2 ± 23.3 0.050
Pathology diagnosis
No invasive or in situ cancer
DCIS
DCIS þ carcinoma
Carcinoma
5 (8%)
41 (66%)
13 (21%)
3 (5%)
9 (6%)
113 (76%)
26 (17%)
1 (1%)
0.321
Additional surgical treatment
No
Yes
52 (84%)
10 (16%)
130 (87%)
19 (13%)
0.516
Specification additional surgical treatment
BCS
Mastectomy
BCS þ mastectomy
3 (5%)
5 (8%)
2 (3%)
10 (7%)
7 (5%)
2 (1%)
0.597
Additional SLNB
No
Yes
19 (95%)
1 (5%)
41 (91%)
4 (9%)
1.000
Histopathologic result additional SLNB
Negative
Positive
1 (100%) 4 (100%)
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practice, additional breast MRI has a sensitivity of 67% (95%CI
[47.7e81.5]), a specificity of 77% (95%CI [68.8e83.7]), and a TNR of
91% (95%CI [84.0e95.5]). Table 3 and Fig. 2 present sensitivity,
specificity, and NPV values if another category is used as cut-off
with an area under the curve (AUC) of 0.73 (95%CI [0.62e0.85]).
In preoperative screening, 58 of the 149 patients in the MRI
groupwere diagnosedwith non-high-grade DCIS and 92with high-grade DCIS. In case of non-high-grade DCIS, preoperative breast
MRI had a sensitivity of 50% (95%CI [25.4e74.6]), a specificity of 91%
(95%CI [79.1e97.1]), a PPV of 60% (95%CI 31.2e83.3]), and a NPV of
88% (95%CI [74.9e94.5]). In case of high-grade DCIS, preoperative
breast MRI had a sensitivity of 80% (95%CI [54.1e93.7]), a specificity
of 68% (95%CI [57.3e78.8]), a PPV of 33% (95%CI [20.1e49.8), and a
NPV of 95% (95%CI [84.6e98.7]).
Table 2
MRI characteristics of 149 patients with biopsy-proven DCIS.
n Percentage (%)
Mean size lesion (mm) 33.7 ± 24.9
Enhancement curves
Type 0
Type 1
Type 2
Type 3
4
105
12
28
3
71
8
19
Invasive cancer
No
Yes
103
46
69
31
Additional diagnostics
No
Yes
121
26
81
19
Specifications additional diagnostics
Ipsilateral side - imaging only
Ipsilateral side e biopsy
Contralateral side e imaging only
Contralateral side e biopsy
6
14
2
6
4
11
1
5
Pathology results additional biopsy
Ipsilateral side - benign
Ipsilateral side e malignant
Contralateral side e benign
Contralateral side - malignant
11
5
6
0
48
22
30
Table 3
Diagnostic accuracy with multiple cut-off values for positive MRI result.
n ¼ MRI þ / SR þ n ¼ MRI -/
Cut-off 1 (MRI-finding 1 (-) vs 2,3& 4 (þ)) 21 68
Cut-off 2 (MRI-finding 1&2 (-) vs 3& 4 (þ)) 18 94
Cut-off 3 (MRI-finding 1,2&3 (-) vs 4 (þ)) 11 108
SR ¼ (histopathologic result) surgical resection; Total positive results SR ¼ 27, total neg
MRI-findings: 1) ‘no invasive cancer’; 2) invasive cancer unlikely’; 3) ‘invasive cancer lik
Fig. 2. ROC curve of the MRI result using the pat
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Underestimation of DCIS poses challenges for determining sur-
gical management: in case of a high risk of occult invasive cancer, a
sentinel lymph node biopsy can be considered. Preoperative breast
MRI in patients with biopsy-proven DCIS may be a valuable addi-
tional tool for estimating the risk of occult invasive cancer. How-
ever, the added value of MRI in the diagnostic work-up has not been
clearly established yet. This prospective observational study aimed
to determine the clinical value of MRI in the preoperative detection
of invasive cancer in patients with biopsy diagnosis DCIS. We found
that MRI had a sensitivity of 67%, a specificity of 78%, and a TNR of
91%. Nuclear grade did affect sensitivity. However, for high-grade
DCIS, the sensitivity was only 80%. Preoperative breast MRI did
not affect the underestimation rate (p ¼ 0.207). Moreover, the use
of MRI did not affect the mastectomy rate nor the re-operation rate.
This re-operation rate is in line with a Dutch population based
study on preoperative MRI in women with invasive cancer or DCIS
[8].
To our knowledge, this is the first prospective study focusing on
preoperative breast MRI for the detection of occult invasive cancer
in patients with biopsy-proven DCIS. A limited number of studies
have addressed the effect of MRI on the detection of occult breast
cancer in patients with biopsy-proven DCIS, [9e16], but most ofSR - Sensitivity (95% CI) Specificity (95% CI) TNR (95% CI)
78% (58.9e89.7) 56% (46.9e64.2) 92% (83.1e96.5)
67% (47.7e81.5) 77% (68.8e83.7) 91% (84.0e95.5)
41% (24.5e59.3) 89% (81.5e93.2) 87% (80.0e92.0)
ative results SR ¼ 122.
ely to be present’; 4) ‘invasive cancer present’.
hological examination as the gold standard.
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clusion of patients was based on the availability of MRI data of these
patients. The large differences in underestimate rates, from 14 to
55%, indicate the likelihood of bias in these studies [9e16]. In most
of these studies, the underestimation ratewas between 20 and 25%,
which is in line with the underestimation rate of 20% that we found
[1,2]. As far as we know, the only other prospective study is a study
by Deurloo et al., but it is not clear how patients in that study were
selected for MRI [11].
Our finding that preoperative MRI has a NPV of 95% in case of
high-grade DCIS suggests that MRI can be of value in excluding the
presence of occult breast cancer. This is in line with the findings of
Deurloo et al., who also concluded that MRI is especially valuable in
excluding the presence of occult breast cancer [11].
On the other hand, our finding that the sensitivity of MRI is too
low to be of use in identifying patients with occult breast cancer is
in contrast with several studies that concluded that it is possible to
use MRI to detect some of the occult breast cancers, without
attempting to determine the sensitivity of MRI in doing this
[9,12,13,15,16]. In studies of Goto et al. and Harowitz et al., the
sensitivity of MRI was presented as ROC curves with an AUC of 0.71
and 0.719, respectively, [10,14], which is in line with our finding of
an AUC of 0.73. However, Goto et al. nevertheless concluded that
MRI is potentially useful, without clearly specifying how [10].
Harowitz et al. arrived at a firmer conclusion and stated that MRI
can be used to identify patients at the highest risk of occult breast
cancer [14].
The impact of preoperative MRI for DCIS on re-intervention
rates remains controversial [17]. Some studies claimed that MRI
allowed for a more accurate determination of the extent of disease
without reporting on re-intervention rates, [13,18,19], and some
others also reported a lower re-intervention rate [20,21]. However,
some of the larger studies did not find lower re-excision rates
[8,22e24]. A study by So et al. could not find an effect on the
number of cavity shavings to obtain a free margin [25]. Our study
could also not advocate preoperative MRI as a means to plan BCS
based on re-intervention rates, since we found no differences in re-
operation rates between the MRI group and non-MRI group.
A widely held concern regarding the use of preoperative MRI in
diagnostic work-up for DCIS is the supposed risk of a subsequent
increase of mastectomies. We found that MRI did not result in
higher mastectomy rates, which is in line with some studies that
also reported no effect of MRI on mastectomy rates [21,23]. By
contrast, the majority of the studies on the effect of MRI on mas-
tectomy rates reported an increased rate [8,20,22,24,26]. Differ-
ences between these studies are hard to explain but are probably
related to the radiologists’ interpretations of the MRI images.
Another concern regarding preoperative MRI for DCIS is the
assumed subsequent increase of additional biopsies [27]. In the
current study, additional biopsies were performed of 20 lesions,
and only six of these biopsies demonstrated the presence of addi-
tional ipsilateral disease (5 DCIS, and 1 invasive carcinoma). No
contralateral malignancies were detected. Although in the current
study, MRI only resulted in detecting additional cancers in 4% of the
included patients, previously published numbers about additional
biopsies ranged from 3 to 30% [20e23,28]. Benveniste et al. studied
in detail the additional or invasive sites of disease detected by
means of MRI after diagnosis of pure DCIS. Additional biopsies were
performed in 30% of the patients, and 26% of these extra biopsies
led to diagnoses of additional or invasive sites of disease. In contrast
to our study, Benveniste et al. only detected contralateral additional
or invasive sites of disease [28].
This study has several limitations. First of all, it was a single
center study that did not randomize patients between MRI or no
MRI. Fortunately, we were able to include all the patients that didnot want to receive preoperativeMRI in our analysis. No differences
in patient characteristics were found except that the mean age was
slightly higher in the non-MRI group. A decline in MRI rate with
increasing age is in line with the results of Tuttle et al. [29]
Therefore, we assume that this cohort is representative and that the
risk of selection bias is negligible. Another limitation is that the coil
that was placed to mark the biopsy site may have resulted in ar-
tefacts, which sometimes makes the evaluation of MRI images
challenging. Besides, suspect lesions may have been small and may
have had the same size as the biopsy needles that were used.
Consequently, all suspect tissue was removed in those cases, and
MRI resulted in post-biopsy images with normal background tissue.
However, in case of significantly extended disease, MRI should have
been able to detect these lesions. The area around the coil where
artefacts may occur is small, 3e5 mm, but in some cases this equals
the area of the initial calcifications. Therefore, evaluation of the
remaining breast tissue was still feasible. Besides, post-biopsy but
preoperative MRI is based on current clinical practice, whichmakes
these data applicable to daily practice.
Although improvement of diagnostic performance was seen in
patients with high-grade DCIS, unfortunately the overall sensitivity
of MRI remained poor. Our results and the diverging results of
previous studies highlight the difficulty of interpreting MRI in case
of DCIS. Consequently, assessment of DCIS with MRI is not the
answer to assess the risk of occult invasive cancer and thereby
improve the selection of patients for a SLNB.
Conclusion
In patients with biopsy-proven DCIS, negativeMRI could reliably
identify patients without invasive breast cancer. However, addi-
tional preoperative breast MRI cannot reliably predict the presence
of invasive cancer in patients with pure DCIS. Therefore, preoper-
ative breast MRI in patients with biopsy proven DCIS cannot be
used in the selection of patients for a SLNB.
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